Sofwave to Participate in Jefferies Global Healthcare Conference

Sofwave Medical Ltd., an innovative player in the field of non-invasive aesthetic medical devices, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025, in New York. Assaf Korner, the company's Chief Financial Officer, will present a corporate overview and engage in one-on-one investor meetings to showcase the company's growth and potential in the aesthetic medicine market.

The presentation is set for June 5, 2025, at 11:05 a.m. ET and will also be available via webcast, allowing interested parties to access the insights shared by Sofwave leaders.

Sofwave is recognized for its proprietary technology, SUPERB™ (Synchronous Ultrasound Parallel Beam), which has received FDA clearance for multiple applications, including wrinkle reduction, eyebrow lifting, and improving skin laxity in areas such as the arms and beneath the chin. The technology is also utilized for the temporary improvement of cellulite and the treatment of acne scars, positioning Sofwave as a comprehensive solution provider for aesthetic practitioners.

Further enhancing its product offerings is the Pure Impact™ module, featuring 4th generation EMS technology designed for muscle toning, which is also FDA cleared. This underscores Sofwave's commitment to delivering smart, effective, and safe aesthetic solutions that empower physicians to meet their patients' diverse needs.

As Sofwave heads into the conference, investor attention may focus on the company’s innovative technologies and market strategy, signaling a promising trajectory in the burgeoning aesthetic medical device industry. For more information, interested parties are encouraged to contact the company or its investor relations representative, Brian Ritchie of LifeSci Advisors.

Sofwave Medical Ltd. (TASE: SOFW) is poised for a critical period of visibility as it participates in the Jefferies Global Healthcare Conference from June 3-5, 2025. This engagement offers a platform for the company to showcase its innovative technological advancements and strategic direction to a wider audience of potential investors. As the Chief Financial Officer, Assaf Korner, presents the corporate overview on June 5, the market will be closely monitoring the insights he shares regarding Sofwave's growth trajectory and financial health.

The company’s proprietary SUPERB™ technology, which focuses on non-invasive procedures for wrinkle reduction and skin rejuvenation, aligns well with current trends in the aesthetic and wellness industry. As consumers increasingly prioritize non-surgical options for cosmetic improvements, Sofwave's FDA-cleared solutions position it favorably in a competitive market. The expanding interest in aesthetic treatments is expected to drive revenue growth, making Sofwave an attractive investment opportunity.

Moreover, the integration of technologies like the Pure Impact™ module for muscle toning reflects Sofwave's commitment to expanding its product offerings. Investors should assess how these innovations can enhance market penetration and revenue diversification.

As Sofwave participates in the conference, keep an eye on key indicators such as market response to its technologies, updates on financial performance, and potential partnerships or collaborations announced during the event. Such developments could serve as catalysts for share price appreciation.

Overall, investors looking for exposure to the healthcare and aesthetic segments may find Sofwave compelling. However, potential investors should conduct thorough due diligence considering the volatile nature of medical technology stocks. With a balanced approach and keen focus on Sofwave's market positioning, investors can make informed decisions ahead of the conference.